Eisai authorized to sell Alzheimer's drug in China
Eisai and Biogen have now received approval for their new Alzheimer's drug, Leqembi, in China. Around 10 million people in the People's Republic suffer from the disease. The drug is not yet sold in Europe.
By Redaktion Table